BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38330795)

  • 1. Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.
    Peng C; Li X; Tang W; Zhu W; Yan P; Chen J; Zhang X; Guo Q; Wu Q; Wang Q; Liu N; Ma A; Lu Y; Lv P; Liu J; Xie P
    Int Immunopharmacol; 2024 Mar; 129():111578. PubMed ID: 38330795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
    Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
    Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
    Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
    Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Takekuma M; Mori K; Iida T; Kurihara K; Saitou M; Tokunaga H; Kawana K; Ikeda M; Satoh T; Saito T; Miyagi E; Nagai Y; Furusawa A; Kawano Y; Kawano K; Tabata T; Ota Y; Hayase R; Mikami M; Sugiyama T
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):697-705. PubMed ID: 28785994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study.
    Xu X; Li R; Zhu P; Zhang P; Chen J; Lin Y; Chen Y
    World J Surg Oncol; 2021 Aug; 19(1):231. PubMed ID: 34362384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
    Xiao Y; Cheng H; Wang L; Yu X
    J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital: Thailand's Largest Tertiary Referral Center.
    Ruengkhachorn I; Leelaphatanadit C; Therasakvichya S; Hunnangkul S
    Int J Gynecol Cancer; 2016 Jul; 26(6):1154-61. PubMed ID: 27051060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy strategy and its prognostic significance for patients with locoregional recurrent cervical cancer after radical hysterectomy: a multicenter retrospective 10-year analysis.
    Shan M; Deng Y; Zou W; Fan S; Li Y; Liu X; Wang J
    BMC Cancer; 2023 Sep; 23(1):905. PubMed ID: 37752476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.
    Lu Y; Huang H; Yang H; Hu X; Liu M; Huang C; Feng X; Chen X; Jiang Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4327-4338. PubMed ID: 36075994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
    Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
    Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for metastatic and recurrent cervical cancer.
    Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
    Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum squamous cell carcinoma antigen level and magnetic resonance imaging for the prognosis of locally advanced cervical cancer.
    Gu LN; Yu JW; Jiang L; Liu TB; Xu Y
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):668-678. PubMed ID: 38305609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
    Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.